Opus Genetics amends bylaws to enhance stockholder rights; sues Sandoz over RYZUMVI

Opus Genetics, Inc.

Bylaws amended: written consent requirements eliminated; 20% threshold to call special meeting.
Stockholder removal threshold reduced to simple majority; amendment threshold also reduced to simple majority.
Filed patent infringement suit against Sandoz in NJ over ANDA for generic RYZUMVI; seeks injunction.
Suit filed with partner FamyGen Life Sciences; Opus intends to vigorously enforce RYZUMVI IP rights.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Opus Genetics, Inc.: Amended and restated bylaws to enhance stockholder rights, including reducing thresholds for actions by written consent, calling special meetings, removing directors, and amending bylaws (effective 2025-03-19).

Change: bylaw amendment
Effective: 2025-03-19

Exact text from the filing

On March 19, 2025, in connection with a periodic review of the bylaws of Opus Genetics, Inc. (the “ Company ”), the Company’s board of directors adopted amended and restated bylaws of the Company (the bylaws, as so amended and restated, the “ Amended and Restated Bylaws ”), effective immediately.

View on SEC.gov

55 governance changes filed in the last 30 days. Browse all governance changes →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001999371-25-002866

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.